Valneva’s chikungunya vaccine Ixchiq now authorised in EU for adolescents aged 12 and above

1 April 2025 - With this extension, Ixchiq, the first vaccine against the chikungunya virus, is now available for administration ...

Read more →

European Commission approves Pfizer’s RSV vaccine Abrysvo to help protect adults aged 18-59 against RSV lower respiratory tract disease

1 April 2025 - Abrysvo is the first and only RSV vaccine approved in the European Union for non-pregnant adults ...

Read more →

European Commission approves Merck’s Capvaxive (pneumococcal 21 valent conjugate vaccine) for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults

26 March 2025 - EC decision marks the fourth approval for Capvaxive for pneumococcal vaccination in adults ...

Read more →

Valneva receives EMA’s positive CHMP opinion for adolescent label extension for chikungunya vaccine Ixchiq

28 February 2025 - If granted, Ixchiq will become the first vaccine against the chikungunya virus available in the EU ...

Read more →

European Commission approves CSL and Arcturus Therapeutics’ Kostaive, the first self-amplifying mRNA COVID-19 vaccine

14 February 2025 - Kostaive represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to ...

Read more →

Highlights from the 27-30 January 2025 CHMP meeting

31 January 2025 - Eight new medicines recommended for approval; one positive opinion for a medicine intended for use outside the ...

Read more →

GSK’s Shingrix new pre-filled syringe presentation accepted for review by EMA

27 January 2025 - If approved, the new presentation will offer a convenient administration option to healthcare professionals. ...

Read more →

GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission

27 November 2024 - New fully liquid presentation means reconstitution is not needed before use. ...

Read more →

Novavax's updated 2024-2025 Nuvaxovid COVID-19 vaccine receives authorisation in the EU

9 October 2024 - Novavax today announced that the European Commission granted marketing authorisation for Novavax's updated 2024-2025 Nuvaxovid COVID-19 vaccine ...

Read more →

GSK’s Menveo meningococcal vaccine in new single-vial, fully liquid presentation receives positive European CHMP opinion

24 September 2024 - Marketing authorisation in EU expected by November 2024. ...

Read more →

Bavarian Nordic receives EMA approval of mpox vaccine for adolescents

19 September 2024 - MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review ...

Read more →

Valneva submits label extension applications for its chikungunya vaccine Ixchiq to EMA and Health Canada

18 September 2024 - To potentially include adolescents and antibody persistence up to two years. ...

Read more →

EMA Committee for Medicinal Products for Human Use adopts positive opinion recommending authorisation of Moderna's COVID-19 mRNA vaccine targeting the SARS-COV-2 variant JN.1

5 September 2024 - Moderna's updated COVID-19 mRNA vaccine will be available for the 2024-2025 vaccination season, pending a European ...

Read more →

European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus vaccine for adults aged 50-59 at increased risk

29 August 2024 - This follows approval in US, with other countries anticipated, including Japan later this year. ...

Read more →

Moderna receives European Commission approval for RSV vaccine mRESVIA

23 August 2024 - Moderna today announced that the European Commission has granted marketing authorisation for mResvia (mRNA-1345), an mRNA respiratory ...

Read more →